{"id":18263,"date":"2013-06-26T11:40:07","date_gmt":"2013-06-26T09:40:07","guid":{"rendered":"https:\/\/ocasapiens-dweb.blogautore.repubblica.it\/?p=18263"},"modified":"2021-09-26T14:39:51","modified_gmt":"2021-09-26T12:39:51","slug":"restauri","status":"publish","type":"post","link":"https:\/\/archivio.ocasapiens.org\/index.php\/2013\/06\/26\/restauri\/","title":{"rendered":"Restauri"},"content":{"rendered":"<p><img decoding=\"async\" src=\"http:\/\/y.delfi.ua\/norm\/7696\/211364_qDrExl.jpeg\" alt=\"\" \/><br \/>\nSul <em>British Medical Journal<\/em>, <span style=\"color: #333333; font-family: Georgia, 'Bitstream Charter', serif; font-size: 14px; line-height: 20.296875px;\">Peter Doshi, Kay Dickersin, David Healy, Swaroop Vedula e Tom Jefferson hanno lanciato l&#8217;iniziativa <a href=\"http:\/\/www.bmj.com\/content\/346\/bmj.f2865\" target=\"_blank\" rel=\"noopener\"><strong>Restoring Invisible and Abandoned Trials<\/strong><\/a> (RIAT), altro fronte nella battaglia contro chi non pubblica &#8211; o pubblica solo parzialmente \u00a0i dati degli esperimenti clinici che non corrispondono alle aspettative aziendali.<\/span><\/p>\n<p><span style=\"color: #333333; font-family: Georgia, 'Bitstream Charter', serif; font-size: 14px; line-height: 20.296875px;\">Hanno raccolto<\/span><br \/>\n<em>around 178.000 pages of previously confidential company research documents. For drugs such as paroxetine, quetiapine, and gabapentin, litigation over illegal off-label marketing put thousands of pages of trial reports in the public domain. Other trial reports, such as for oseltamivir and clopidogrel, were obtained through new freedom of information policies at the European Medicines Agency (EMA)&#8230; \u00a0We expect that other independent groups will also have access to many additional trial reports.<\/em><\/p>\n<p>Esperimenti conclusi addirittura nel 1983, fatti dal Gotha della categoria, da Astra a Zeneca&#8230; Serve aiuto:<\/p>\n<p><em>We call on others to join us, to contribute trial documents they have obtained from public sources that need publishing or republishing, and to help us with the writing. We need volunteers to act in place of those who should have but did not make trial reports visible and accessible.<\/em><\/p>\n<p><span style=\"border: 0px; margin: 0px; padding: 0px; vertical-align: baseline; color: #333333; font-family: Georgia, 'Bitstream Charter', serif; font-size: 14px; line-height: 20.296875px;\">Le responsabili di <em>PLoS Medicine<\/em> <a href=\"http:\/\/www.bmj.com\/content\/346\/bmj.f3601\" target=\"_blank\" rel=\"noopener\"><strong>spiegano,<\/strong><\/a> perch\u00e9 la rivista ha aderito:<\/span><\/p>\n<p><em>Nothing better underscores the urgency and importance of the RIAT proposal than the list of abandoned trials that accompanies it. Read it and weep: on the list are clinical trials for drugs used by millions of people, including zanamivir, atorvastatin, gabapentin, and paroxetine&#8230; Secrecy and selective reporting were an integral part of the system. Reforms such as trial registration and mandatory results reporting will improve things in the future but can do nothing about the flawed evidence of the past.<\/em><\/p>\n<p>L&#8217;idea non \u00e8 soltanto di verificare l&#8217;evidence passata e trarne le conseguenze per le terapie da prescrivere o meno, ma anche di fare da deterrente. Se Big Pharma non permetter\u00e0 ai ricercatori di pubblicare tutti i dati, ci penseranno altri senza conflitto di interessi e senza NDA.<\/p>\n<p><a href=\"http:\/\/blogs.plos.org\/speakingofmedicine\/2013\/06\/13\/restoring-invisible-and-abandoned-trials-a-creative-approach-to-a-public-good-now-a-creative-approach-to-implementation-is-needed\/\" target=\"_blank\" rel=\"noopener\"><strong>Ostacoli tanti<\/strong><\/a> &#8230;<\/p>\n<p style=\"text-align: center;\">*<\/p>\n<p style=\"text-align: left;\"><strong>Ripulita all&#8217;impact factor <\/strong><\/p>\n<p style=\"text-align: left;\">L&#8217;iniziativa <a href=\"http:\/\/am.ascb.org\/dora\/\" target=\"_blank\" rel=\"noopener\"><strong>DORA<\/strong><\/a> comincia a dare frutti? Per <a href=\"http:\/\/wokinfo.com\/media\/pdf\/jcr-suppression.pdf\" target=\"_blank\" rel=\"noopener\">abuso<\/a> di autocitazioni e\/o citazioni incrociate tra riviste dello stesso gruppo editoriale, Thomson Reuters ha escluso <a href=\"http:\/\/admin-apps.webofknowledge.com\/JCR\/static_html\/notices\/notices.htm#editorial_information\" target=\"_blank\" rel=\"noopener\"><strong>66 riviste<\/strong><\/a> dalla classifica che pubblica ogni anno nei\u00a0<em>Journal Citation Reports<\/em>.\u00a0Erano 51 nel 2012 e 34 nel 2011.<\/p>\n<p style=\"text-align: center;\">*<\/p>\n<p style=\"text-align: left;\"><strong>Home-made <\/strong><\/p>\n<p style=\"text-align: left;\">Jeffrey Beall <a href=\"http:\/\/scholarlyoa.com\/2013\/06\/25\/publishers-journals-boast-amazingly-high-impact-factors\/\" target=\"_blank\" rel=\"noopener\">segnala<\/a> un altro <a href=\"http:\/\/www.iaria.org\/speakers\/PetreDini.html\" target=\"_blank\" rel=\"noopener\"><strong>predone<\/strong><\/a>: il titolare dell&#8217;<a href=\"http:\/\/www.iaria.org\/\" target=\"_blank\" rel=\"noopener\">International Academy, Research, and Industry Association<\/a> che s&#8217;inventa sensazionali impact factor. Come l&#8217;editore sotto presunta &#8220;<a href=\"http:\/\/22passi.blogspot.it\/2013\/04\/experimental-results-on-sub-micro.html\" target=\"_blank\" rel=\"noopener\"><strong>egida dell&#8217;Unesco<\/strong><\/a>&#8221; al quale il dott. Celani &amp; Co. hanno pagato la pubblicazione del loro <strong><a href=\"http:\/\/www.iiste.org\/PDFshare\/CMRV3N3-27-56.pdf\" target=\"_blank\" rel=\"noopener\">d\u00e9pliant<\/a> <a href=\"http:\/\/www.kresenn.com\/#!articles\" target=\"_blank\" rel=\"noopener\">aziendale<\/a><\/strong>.<\/p>\n<p style=\"text-align: left;\">Come i titolari di Nexus, 22 passi e il &#8220;prof.&#8221; Valenzi (anche se in un inglese meno spassoso), vende\u00a0<strong><a href=\"http:\/\/www.iaria.org\/conferences.html\" target=\"_blank\" rel=\"noopener\">gite<\/a> <\/strong>presunte scientifiche a geni incompresi e seguaci, di cui quattro a Roma solo in questa settimana. Prezzo salato nonostante <a href=\"http:\/\/www.iaria.org\/confsponsors.html\" target=\"_blank\" rel=\"noopener\"><strong>innumerevoli sponsor<\/strong><\/a> tra cui UniBo, PoliTo e UniUrbino &#8211; sar\u00e0 un caso?<\/p>\n<p style=\"text-align: left;\">\n<p style=\"text-align: left;\">\n<p style=\"text-align: left;\">\n","protected":false},"excerpt":{"rendered":"<p>Sul British Medical Journal, Peter Doshi, Kay Dickersin, David Healy, Swaroop Vedula e Tom Jefferson hanno lanciato l&#8217;iniziativa Restoring Invisible and Abandoned Trials (RIAT), altro fronte nella battaglia contro chi non pubblica &#8211; o pubblica solo parzialmente \u00a0i dati degli esperimenti clinici che non corrispondono alle aspettative aziendali. Hanno raccolto around 178.000 pages of previously&hellip; <a class=\"more-link\" href=\"https:\/\/archivio.ocasapiens.org\/index.php\/2013\/06\/26\/restauri\/\">Continua a leggere <span class=\"screen-reader-text\">Restauri<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[819,2147,2405,3465,3564,4535,5019,5857,7589],"class_list":["post-18263","post","type-post","status-publish","format-standard","hentry","category-cronaca","tag-big-pharma","tag-editoria-predona","tag-esperimenti-clinici","tag-impact-factor","tag-integrita","tag-misconduct","tag-open-access","tag-riat","tag-scamferences","entry"],"_links":{"self":[{"href":"https:\/\/archivio.ocasapiens.org\/index.php\/wp-json\/wp\/v2\/posts\/18263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/archivio.ocasapiens.org\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/archivio.ocasapiens.org\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/archivio.ocasapiens.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/archivio.ocasapiens.org\/index.php\/wp-json\/wp\/v2\/comments?post=18263"}],"version-history":[{"count":2,"href":"https:\/\/archivio.ocasapiens.org\/index.php\/wp-json\/wp\/v2\/posts\/18263\/revisions"}],"predecessor-version":[{"id":41607,"href":"https:\/\/archivio.ocasapiens.org\/index.php\/wp-json\/wp\/v2\/posts\/18263\/revisions\/41607"}],"wp:attachment":[{"href":"https:\/\/archivio.ocasapiens.org\/index.php\/wp-json\/wp\/v2\/media?parent=18263"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/archivio.ocasapiens.org\/index.php\/wp-json\/wp\/v2\/categories?post=18263"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/archivio.ocasapiens.org\/index.php\/wp-json\/wp\/v2\/tags?post=18263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}